Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
This study has been completed.
First Received: September 15, 2003   Last Updated: November 20, 2009   History of Changes
Sponsor: Hoffmann-La Roche
Information provided by: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT00069095
  Purpose

This 4 arm study will assess the efficacy and safety of oral Xeloda, or intravenous (iv) fluorouracil/leucovorin, in combination with iv Eloxatin (oxaliplatin) with or without iv Avastin as a first-line treatment in patients with metastatic colorectal cancer. Patients will be randomized to receive 1) XELOX (Xeloda 1000mg/m2 po bid on days 1-15 + oxaliplatin), in 3 week cycles, 2) FOLFOX-4 (oxaliplatin + leucovorin + 5-FU in 2 week cycles), 3) XELOX + Avastin (7.5 mg iv on day 1)in 3 week cycles or 4)FOLFOX-4 + Avastin (5mg iv on day 1)in 2 week cycles. The anticipated time on study treatment is until disease progression and the target sample size is 500+ individuals.


Condition Intervention Phase
Colorectal Cancer
Drug: capecitabine [Xeloda]
Drug: Oxaliplatin
Drug: Leucovorin
Drug: 5 FU
Drug: Avastin
Phase III

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Factorial Assignment, Safety/Efficacy Study
Official Title: A Randomized, Open-label Study Comparing the Effect of First-line Treatment With Intermittent Xeloda Versus Fluorouracil/Leucovorin, Both in Combination With Eloxatin With or Without Avastin, on Tumor Progression in Patients With Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Non-inferiority of XELOX vs FOLFOX, with respect to time to progression or death, and superiority of Avastin vs placebo. [ Time Frame: Event driven ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall survival, overall response rate, time to response, duration of response, time to treatment failure. [ Time Frame: Event driven ] [ Designated as safety issue: No ]
  • AEs, laboratory tests. [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 2035
Study Completion Date: November 2009
Arms Assigned Interventions
1: Experimental Drug: capecitabine [Xeloda]
1000mg/m2 po bid on days 1-15 of each 3 week cycle.
2: Active Comparator Drug: Oxaliplatin
As prescribed in 2 week cycles.
Drug: Leucovorin
As prescribed, in 2 week cycles
Drug: 5 FU
As prescribed, in 2 week cycles.
3: Active Comparator Drug: capecitabine [Xeloda]
1000mg/m2 po bid on days 1-15 of each 3 week cycle.
Drug: Oxaliplatin
As prescribed in 3 week cycles
Drug: Avastin
7.5mg iv on day 1 in each 3 week cycle
4: Active Comparator Drug: Leucovorin
As prescribed, in 2 week cycles
Drug: 5 FU
As prescribed, in 2 week cycles.
Drug: Avastin
5mg iv on day 1 of each 2 week cycle

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adult patients >=18 years of age;
  • metastatic colorectal cancer;
  • >=1 target lesion.

Exclusion Criteria:

  • previous treatment with oxaliplatin or bevacizumab;
  • previous systemic chemotherapy or immunotherapy for advanced or metastatic disease;
  • progressive disease during or within 6 months of completion of previous adjuvant therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00069095

  Hide Study Locations
Locations
United States, California
Berkeley, California, United States, 94704
Los Angeles, California, United States, 90057
San Diego, California, United States, 92123
Greenbrae, California, United States, 94904
Fountain Valley, California, United States, 92708
Fullerton, California, United States, 92835
Gilroy, California, United States, 95020
Palo Alto, California, United States, 94304
Orange, California, United States, 92868
United States, Connecticut
Waterbury, Connecticut, United States, 06708
Norwich, Connecticut, United States, 06360
United States, Florida
Gainesville, Florida, United States, 33610-0277
Tampa, Florida, United States, 33612
New Port Richey, Florida, United States, 34652
Boca Raton, Florida, United States, 33486
Tampa, Florida, United States, 33607
Jacksonville, Florida, United States, 32207
United States, Georgia
Atlanta, Georgia, United States, 30341
United States, Illinois
Peoria, Illinois, United States, 61615-7828
Chicago, Illinois, United States, 60640
Elk Grove Village, Illinois, United States, 60007
United States, Kentucky
Lexington, Kentucky, United States, 40536-0098
United States, Louisiana
New Orleans, Louisiana, United States, 70121
United States, Maine
Scarborough, Maine, United States, 04074
United States, Massachusetts
Boston, Massachusetts, United States, 02135
United States, Michigan
Ann Arbor, Michigan, United States, 48106
United States, Minnesota
St Louis Park, Minnesota, United States, 55416
United States, Nevada
Las Vegas, Nevada, United States, 89106
United States, New Jersey
New Brunswick, New Jersey, United States, 08901
East Orange, New Jersey, United States, 07019
Hamilton, New Jersey, United States, 08690
United States, New Mexico
Farmington, New Mexico, United States, 87401
Albuquerque, New Mexico, United States, 87131-0001
United States, New York
Syracuse, New York, United States, 13210
New York, New York, United States, 10021
Rochester, New York, United States, 14623
United States, North Carolina
Charlotte, North Carolina, United States, 28233-3549
Charlotte, North Carolina, United States, 28203
United States, North Dakota
Fargo, North Dakota, United States, 58122
Bismarck, North Dakota, United States, 58501
United States, Pennsylvania
Sayre, Pennsylvania, United States, 18840
Upland, Pennsylvania, United States, 19013
United States, Rhode Island
Providence, Rhode Island, United States, 02906
United States, South Carolina
Charleston, South Carolina, United States, 29425
Columbia, South Carolina, United States, 29209
United States, Tennessee
Memphis, Tennessee, United States, 38120
United States, Texas
Houston, Texas, United States, 77024
United States, Vermont
Burlington, Vermont, United States, 05401
United States, Virginia
Richmond, Virginia, United States, 23294
Australia
Sydney, Australia, 2050
Port Macquarie, Australia, 2444
Perth, Australia, 6000
Melbourne, Australia, 3181
Adelaide, Australia, 5011
Footscray, Australia, 3011
Melbourne, Australia, 3002
Brisbane, Australia, 4101
Sydney, Australia, 2031
Melbourne, Australia, 3128
Kurralta Park, Australia, 5037
St. Leonards, Australia, 2065
Fitzroy, Australia, 3065
Malvern, Australia, 3144
Sydney, Australia, 2139
Austria
Wien, Austria, 1090
Wels, Austria, 4600
Brazil
Jaú, Brazil, 17210-080
Sao Paulo, Brazil, 05403-000
Rio de Janeiro, Brazil, 20231-050
Canada, Alberta
Calgary, Alberta, Canada, T2N 4N2
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
Victoria, British Columbia, Canada, V8R 6V5
Surrey, British Columbia, Canada, V3V 1Z2
Kelowna, British Columbia, Canada, V1Y 5L3
Vancouver, British Columbia, Canada, V5Z 4E6
North Vancouver, British Columbia, Canada, V7L 2L7
Canada, Manitoba
Winnipeg, Manitoba, Canada, R2H 2A6
Canada, Nova Scotia
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Ottawa, Ontario, Canada, K1H 8L6
Toronto, Ontario, Canada, M4N 3M5
Toronto, Ontario, Canada, M9N 1N8
Mississauga, Ontario, Canada, L5M 2N1
Toronto, Ontario, Canada, M5G 1X5
Hamilton, Ontario, Canada, L8V 5C2
London, Ontario, Canada, N6A 4L6
Toronto, Ontario, Canada, M5G 2M9
St. Catharines, Ontario, Canada, L2R 7C6
Oshawa, Ontario, Canada, L1G 2B9
Canada, Quebec
Levis, Quebec, Canada, G6V 3Z1
Montreal, Quebec, Canada, H2L 4M1
Quebec City, Quebec, Canada, G1R 2J6
Montreal, Quebec, Canada, H4J 1C5
Montreal, Quebec, Canada, H1T 2M4
China
Beijing, China, 100021
Shanghai, China, 200025
Wuhan, China, 430030
Shanghai, China, 200092
Guangzhou, China, 510060
Guangdong, China, 510515
Jiangsu, China, 210009
Shandong, China, 250117
Beijing, China, 100853
Tianjin, China, 300060
Jiangxi, China, 330000
Czech Republic
Hradec Kralove, Czech Republic, 500 36
Chomutov, Czech Republic, 430 12
Brno, Czech Republic, 656 53
Ostrava, Czech Republic, 708 52
Denmark
Odense, Denmark, 5000
København, Denmark, 2100
Herlev, Denmark, 2730
Finland
Tampere, Finland, 33520
Helsinki, Finland, 00029
Turku, Finland, 20520
France
Nice, France, 06202
Brest, France, 29609
Saint Herblain, France, 44093
Colmar, France, 68024
Metz, France, 57070
Chambray-lès-tours, France, 37044
Nimes, France, 30029
Besancon, France, 25030
Nice, France, 06189
Saint Herblain, France, 44805
Toulouse, France, 31052
Lyon, France, 69373
Boulogne-billancourt, France, 92104
Rouen, France, 76031
Bobigny, France, 93009
Grenoble, France, 38100
Paris, France, 75651
Paris, France, 75014
Pierre Benite, France, 69495
Dijon, France, 21000
Paris, France, 75475
Germany
Trier, Germany, 54290
Stralsund, Germany, 18435
Regensburg, Germany, 93053
Halle, Germany, 06120
Bochum, Germany, 44892
Mannheim, Germany, 68167
Hannover, Germany, 30625
Mainz, Germany, 55101
Herne, Germany, 44625
Leipzig, Germany, 04129
Guatemala
Guatemala City, Guatemala, 01015
Guatemala City, Guatemala, 01009
Hong Kong
Hong Kong, Hong Kong
Hungary
Gyor, Hungary, 9023
Budapest, Hungary, 1122
Budapest, Hungary, 1082
Kecskemet, Hungary, 6000
Ireland
Cork, Ireland
Dublin, Ireland, 4
Galway, Ireland
Dublin, Ireland, 8
Israel
Tel Aviv, Israel, 64239
Haifa, Israel, 31096
Petach Tikva, Israel, 49100
Jerusalem, Israel, 91120
Zerifin, Israel, 70300
Italy
Genova, Italy, 16132
Ancona, Italy, 60121
Sassari, Italy, 07100
Parma, Italy, 43100
Genova, Italy, 16132
Reggio Emilia, Italy, 42100
Modena, Italy, 41100
Padova, Italy, 35100
Pavia, Italy, 27100
Korea, Republic of
Seoul, Korea, Republic of, 135-170
Mexico
Mexico City, Mexico, 14000
New Zealand
Christchurch, New Zealand
Norway
Bergen, Norway, 5021
Oslo, Norway, 0407
Tromsø, Norway, 9038
Panama
Panama City, Panama
Portugal
Lisboa, Portugal, 1649-035
Beja, Portugal, 7801-849
Puerto Rico
San Juan, Puerto Rico, 00907
Russian Federation
Moscow, Russian Federation, 115478
Moscow, Russian Federation, 117837
St Petersburg, Russian Federation, 198255
St Petersburg, Russian Federation, 197758
Moscow, Russian Federation, 105229
South Africa
Sandton, South Africa, 2196
Pretoria, South Africa, 0001
Cape Town, South Africa, 7506
Spain
Madrid, Spain, 28007
Barcelona, Spain, 08035
Santander, Spain, 39008
Valencia, Spain, 46010
Madrid, Spain, 28040
Barcelona, Spain, 08907
Valencia, Spain, 46009
Córdoba, Spain, 14004
Madrid, Spain, 28041
Barcelona, Spain, 08036
Madrid, Spain, 28046
Madrid, Spain, 28034
Zaragoza, Spain, 50009
Leganes, Spain, 28911
Granada, Spain, 18014
Málaga, Spain, 29010
Sweden
Västerås, Sweden, 72189
Uppsala, Sweden, 75185
Stockholm, Sweden, 17176
Gaevle, Sweden, 80187
Karlstad, Sweden, 65185
Switzerland
Bern, Switzerland, 3010
Geneve, Switzerland, 1205
Taiwan
Taipei, Taiwan, 100
Taipei, Taiwan, 114
Taipei, Taiwan, 112
Kueishan, Taiwan, 333
Thailand
Bangkok, Thailand, 10700
Khon Kaen, Thailand, 40002
Bangkok, Thailand, 10110
Turkey
Istanbul, Turkey, 34300
Izmir, Turkey, 35100
United Kingdom
Guildford, United Kingdom, GU2 5XX
Sutton, United Kingdom, SM2 5PT
Newcastle Upon Tyne, United Kingdom, NE7 7DN
Birmingham, United Kingdom, B18 7QH
Glasgow, United Kingdom, G12 0YN
Aberdeen, United Kingdom, AB25 2ZN
Northwood, United Kingdom, HA6 2RN
Taunton, United Kingdom, TA1 5DA
Southampton, United Kingdom, SO9 4PE
Salisbury, United Kingdom, SP2 8BJ
Cardiff, United Kingdom, CF14 2TL
Derby, United Kingdom, DE1 2QY
London, United Kingdom, SW3 6JJ
Hull, United Kingdom, HU8 9HE
Maidstone, United Kingdom, ME16 9QQ
Nottingham, United Kingdom, NG5 1PB
Plymouth, United Kingdom, PL6 8DH
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche ( Disclosures Group )
Study ID Numbers: NO16966
Study First Received: September 15, 2003
Last Updated: November 20, 2009
ClinicalTrials.gov Identifier: NCT00069095     History of Changes
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Antimetabolites
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Antineoplastic Agents
Colonic Diseases
Physiological Effects of Drugs
Leucovorin
Bevacizumab
Rectal Diseases
Oxaliplatin
Neoplasms by Site
Vitamins
Therapeutic Uses
Growth Inhibitors
Angiogenesis Modulating Agents
Micronutrients
Capecitabine
Digestive System Neoplasms
Vitamin B Complex
Growth Substances
Intestinal Diseases
Angiogenesis Inhibitors
Intestinal Neoplasms
Pharmacologic Actions
Neoplasms
Digestive System Diseases
Gastrointestinal Neoplasms
Colorectal Neoplasms

ClinicalTrials.gov processed this record on November 27, 2009